Di Maria Jiang, Shruti Parshad, Luna Zhan, Hao-Wen Sim, Lillian L Siu, Geoffrey Liu, Jeremy D Shapiro, Timothy J Price, Derek J Jonker, Christos S Karapetis, Andrew H Strickland, Wenjiang Zhang, Mark Jeffery, Dongsheng Tu, Siobhan Ng, Sabe Sabesan, Jenny Shannon, Amanda Townsend, Chris J O'Callaghan, Eric X Chen
BACKGROUND: Cetuximab is a standard of care therapy for patients with RAS wild-type (WT) advanced colorectal cancer. Limited data suggest a wide variation in cetuximab plasma concentrations after standard dosing regimens. We correlated cetuximab plasma concentrations with survival and toxicity. METHODS: The CO. 20 study randomized patients with RAS WT advanced colorectal cancer in a 1:1 ratio to cetuximab 400 mg/m2 intravenously followed by weekly maintenance of 250 mg/m2 , plus brivanib 800 mg orally daily or placebo...
December 2023: Clinical Colorectal Cancer